Novo Nordisk saw sales growth for its diabetes and obesity care segment slow in the first half of 2025, confirming investor concern that the company is struggling to fend off competition in the glucagon-like peptide 1 receptor agonists (GLP-1RA) market.

Danish drugmaker Novo Nordisk said on Tuesday it has filed 14 new lawsuits in the United States against the sale of unapproved versions of semaglutide, the active ingredient in its popular weight-loss and diabetes drugs,

Sales of Novo Nordisk's blockbuster Wegovy obesity drug rose 67% in the second quarter despite continued competition from compounded drug makers. The pharma giant last week cut its full-year guidance and named Mike Doustdar as its new CEO.